Raymond, Eric <br/><br/>
Sunitinib paves the way for targeted therapies in neuroendocrine tumors.  [electronic resource] 

 -  Targeted oncology  Dec 2009 
 - 253-4 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1776-260X 
<br/><br/><label>Standard No.: </label>10.1007/s11523-009-0130-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor<br/>Carcinoid Tumor--drug therapy<br/>Cell Line, Tumor<br/>Clinical Trials as Topic<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--therapeutic use<br/>Humans<br/>Indoles--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Lung Neoplasms--drug therapy<br/>Melphalan--therapeutic use<br/>Neovascularization, Pathologic--prevention & control<br/>Neuroendocrine Tumors--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Procarbazine--therapeutic use<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins c-kit<br/>Pyrroles--therapeutic use<br/>Sunitinib<br/>Vinblastine--therapeutic use<br/>Xenograft Model Antitumor Assays